Registry of Lobbyists
Total Number of Communication Reports: 5
Monthly communication reports in the last 6 months: 0
| Subject matters | Details | Categories |
|---|---|---|
|
Health, Research and Development
|
Seeking funding to allow for increased research and development and other expenditures into two clinical-stage antibodies to treat acute respiratory distress syndrome (the primary cause of death from COVID-19) from the Industrial Research Assistance Program and the Strategic Innovation Fund.
|
Grant, Contribution or Other Financial Benefit
|
We are a biopharmaceutical company focused on acquiring, developing and commercializing clinical-stage drugs for indications with clear unmet medical needs.
Pardeep Nijhawan, Chief Executive Officer
End date of the last completed financial year: 2023-09-30
| Government Institution | Funding Received in Last Financial Year | Funding Expected in Current Financial Year |
|---|---|---|
| Innovation, Science and Economic Development Canada (ISED) | $1,405,350.00 | Yes |
Address:
100 Spy Court
Markham, ON L3R 5H6
Canada
Telephone number:
289-800-9600
Fax number:
805-488-2889
Edesa Biotech Research, Inc. does not have any subsidiaries that could have a direct interest in the outcome of the undertaking